

Sheet 1 of 1

Form PTO-1449	U.S. Department of Commerce Patent and Trademark Office	ATTY. DOCKET NO. PB60330	SERIAL NO. 10/561,498
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use several sheets if necessary)</i>		APPLICANT Liddle, et al.	
		FILING DATE 19 Dec 2005	GROUP 1624

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
	5,817,751	06 Oct 2005	Szardenings, et al.			
	4,596,819	24 June 1986	Nicolaides, et al.			
	2007/0208031A1	06 Sept 2007	Borthwick, et al.			
	2007/0185162A1	09 Aug 2007	Borthwick, et al.			
	2005/0148572	07 July 2005	Borthwick, et al.			
	2007/0254888A1	01 Nov 2007	Borthwick, et al.			

FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No
	WO99/47549	23 Sept 1999	WIPO				
	WO2006/067462A1	22 Dec 2005	PCT				
	WO2005/000311A1	22 Oct 2004	PCT				
	WO9937304	29 July 1999	WIPO				
	WO9938844	05 Aug 1999	WIPO				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

OTHER DOCUMENTS (including Author, Title, Date, Volume / Pages, Etc.)			
	Grigorash, <i>et al.</i> , <i>Chem. Heterocycl. Compound</i> , 13(12): 1280-1281 (1977).		
	Kolasa, <i>et al.</i> , <i>J. Org. Chem.</i> , 55(6): 1711-1721 (1990).		
	Pettibone, <i>et al.</i> <i>Drug Development Research</i> , 30(3): 129-142 (1993).		
	V. Stella, <i>Pro Drugs as Novel Drug Delivery Systems, Pro Drugs: An Overview and Definition</i> : 1-115 (1975).		
	Wyatt, <i>et al.</i> <i>Bioorganic & Med. Chem. Letters</i> , 11(10): 1301-1305 (2001).		
	Sarnyai, <i>et al.</i> , <i>Psychoneuroendocrinology</i> , 19(1): 85-117 (1994).		
EXAMINER	/Sabiha Qazi/	DATE CONSIDERED	12/22/2008
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			

n:\tony\cases\pb60330\pto-1449 form 10-10-08.dot